Wu Jiacai, Wu Weigang, Zhou Boping, Li Bin
Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China; School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
Department of Infectious Disease, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology and The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
Trends Biotechnol. 2024 Feb;42(2):228-240. doi: 10.1016/j.tibtech.2023.08.005. Epub 2023 Sep 21.
Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.
表达嵌合抗原受体（CAR）的基因工程免疫细胞已成为癌症免疫治疗中的一种新的变革力量。CAR-T细胞疗法针对血液系统恶性肿瘤的效用已在临床实践中得到验证。目前正在研究其他CAR免疫细胞，以提高CAR疗法在实体瘤中的效力。作为一类新的治疗方式，基于mRNA的疗法在COVID-19 mRNA疫苗之外具有巨大潜力。用mRNA编码的CAR武装免疫细胞代表了癌症及其他领域的一个新前沿，能够在体内生成CAR细胞而不导致转基因整合。在本综述中，我们总结了基于mRNA的CAR免疫疗法的最新进展，并强调了其在新一代活体药物开发中的机遇和挑战。
